Literature DB >> 19542233

Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.

Rajat Puri1, Toshimitsu Suzuki, Kazuhiro Yamakawa, Subramaniam Ganesh.   

Abstract

Lafora progressive myoclonous epilepsy (Lafora disease; LD) is caused by mutations in the EPM2A gene encoding a dual specificity protein phosphatase named laforin. Our analyses on the Epm2a gene knock-out mice, which developed most of the symptoms of LD, reveal the presence of hyperphosphorylated Tau protein (Ser(396) and Ser(202)) as neurofibrillary tangles (NFTs) in the brain. Intriguingly, NFTs were also observed in the skeletal muscle tissues of the knock-out mice. The hyperphosphorylation of Tau was associated with increased levels of the active form of GSK3 beta. The observations on Tau protein were replicated in cell lines using laforin overexpression and knockdown approaches. We also show here that laforin and Tau proteins physically interact and that the interaction was limited to the phosphatase domain of laforin. Finally, our in vitro and in vivo assays demonstrate that laforin dephosphorylates Tau, and therefore laforin is a novel Tau phosphatase. Taken together, our study suggests that laforin is one of the critical regulators of Tau protein, that the NFTs could underlie some of the symptoms seen in LD, and that laforin can contribute to the NFT formation in Alzheimer disease and other tauopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542233      PMCID: PMC2755673          DOI: 10.1074/jbc.M109.009688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  PROGRESSIVE MYOCLONUS EPILEPSY WITH LAFORA BODIES. CLINICAL-PATHOLOGICAL FEATURES.

Authors:  H DE JAGER
Journal:  Epilepsia       Date:  1963-06       Impact factor: 5.864

Review 2.  Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.

Authors:  K Iqbal; I Grundke-Iqbal
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

3.  A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles.

Authors:  T Yamamoto; A Hirano
Journal:  Neuropathol Appl Neurobiol       Date:  1986 Jan-Feb       Impact factor: 8.090

4.  Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies.

Authors:  M Mirabella; R B Alvarez; M Bilak; W K Engel; V Askanas
Journal:  J Neuropathol Exp Neurol       Date:  1996-07       Impact factor: 3.685

5.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205.

Authors:  M Goedert; R Jakes; E Vanmechelen
Journal:  Neurosci Lett       Date:  1995-04-21       Impact factor: 3.046

Review 6.  Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.

Authors:  K Imahori; T Uchida
Journal:  J Biochem       Date:  1997-02       Impact factor: 3.387

7.  Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Cameron A Ackerley; Hannes Lohi; Leonarda Ianzano; Miguel A Cortez; Patrick Shannon; Stephen W Scherer; Berge A Minassian
Journal:  Hum Mol Genet       Date:  2004-04-21       Impact factor: 6.150

8.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

9.  Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.

Authors:  B R Sperber; S Leight; M Goedert; V M Lee
Journal:  Neurosci Lett       Date:  1995-09-08       Impact factor: 3.046

10.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.

Authors:  B A Minassian; J R Lee; J A Herbrick; J Huizenga; S Soder; A J Mungall; I Dunham; R Gardner; C Y Fong; S Carpenter; L Jardim; P Satishchandra; E Andermann; O C Snead; I Lopes-Cendes; L C Tsui; A V Delgado-Escueta; G A Rouleau; S W Scherer
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  26 in total

1.  The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.

Authors:  Pankaj Kumar Singh; Sweta Singh; Subramaniam Ganesh
Journal:  Mol Cell Biol       Date:  2011-11-28       Impact factor: 4.272

Review 2.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 3.  Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.

Authors:  Matthew S Gentry; Carlos Romá-Mateo; Pascual Sanz
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

4.  Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.

Authors:  Yin Wang; Keli Ma; Peixiang Wang; Otto Baba; Helen Zhang; Jack M Parent; Pan Zheng; Yang Liu; Berge A Minassian; Yan Liu
Journal:  Mol Neurobiol       Date:  2013-04-02       Impact factor: 5.590

5.  Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Authors:  Gentzane Sánchez-Elexpuru; José M Serratosa; Marina P Sánchez
Journal:  Epilepsia       Date:  2017-01-18       Impact factor: 5.864

Review 6.  Glycogen and its metabolism: some new developments and old themes.

Authors:  Peter J Roach; Anna A Depaoli-Roach; Thomas D Hurley; Vincent S Tagliabracci
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

7.  The Laforin-like dual-specificity phosphatase SEX4 from Arabidopsis hydrolyzes both C6- and C3-phosphate esters introduced by starch-related dikinases and thereby affects phase transition of alpha-glucans.

Authors:  Mahdi Hejazi; Joerg Fettke; Oliver Kötting; Samuel C Zeeman; Martin Steup
Journal:  Plant Physiol       Date:  2009-12-16       Impact factor: 8.340

Review 8.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

9.  Laforin, the most common protein mutated in Lafora disease, regulates autophagy.

Authors:  Carmen Aguado; Sovan Sarkar; Viktor I Korolchuk; Olga Criado; Santiago Vernia; Patricia Boya; Pascual Sanz; Santiago Rodríguez de Córdoba; Erwin Knecht; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-05-07       Impact factor: 6.150

10.  A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.

Authors:  Yuxin Chen; Michael Vaine; Aaron Wallace; Dong Han; Shengqin Wan; Michael S Seaman; David Montefiori; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.